San Diego, United States
BlossomHill Therapeutics, Inc., founded in 2020, is a burgeoning player in the biopharma sector, recognized for its commitment to tackling pressing medical needs in oncology and autoimmune disorders through innovative small molecule drug discovery. Under the leadership of esteemed scientist J. Jean Cui, Ph.D., and well-versed biotech executive Y. Peter Li, Ph.D., M.B.A., the company leverages cutting-edge science paired with profound industry expertise.
Headquartered in San Diego, California, BlossomHill Therapeutics embodies its slogan, "Addressing urgent unmet medical needs through deeper science, true originality, and rich experience," with an ambitious approach to drug development. The startup's recent $100.00M Series B funding, secured on 01 February 2024, highlights significant investor confidence. This capital influx, led by notable backers including OrbiMed, Vivo Capital, Colt Ventures, Cormorant Asset Management, H&D Asset Management, Plaisance Capital Management LLC, and Hercules Bioventure Partners, positions the company for strategic growth and innovation within the biotechnology and health care industries.
